Colin is the Founder and CEO of Greater Bay Biotechnology (GBBT), which focuses on the research, development and commercialisation of transdermal drug and cell delivery technology with wide applications including the treatment of diseases (e.g. diabetes, cancer) and anti-aging. GBBT is a business supported by City University of Hong Kong (CityUHK) HK Tech 300 Seed and Angel funds, Hong Kong Science and Technology Park (HKSTP) IDEATION programme and HKSAR Government Innovation and Technology Fund’s Technology Start-up Support Scheme for Universities (TSSSU). Under leadership of Mr Ng, GBBT has won numerous domestic and international awards and has developed its business in Hong Kong and Mainland China.

Prior to his current position, Mr Ng has worked in senior roles at Global 500 enterprises including EY, ANZ Bank, Standard Chartered, Prudential, and he has advised major investors of listed companies in the biotechnology and pharmaceutical sectors on strategy, corporate development, incubation and IPO.

Mr Ng has four masters degrees: MSc in Health Sciences and Management from CityUHK, a MSc (Real Estate) from University of Hong Kong, a Master of Applied Finance and Investment from Securities Institute of Australia, a MBA from University of New South Wales & University of Sydney, and a Bachelor of Commerce (Accounting) from University of New South Wales. Mr Ng is a Fellow (FCPA) of Hong Kong Institute of Certified Public Accountants, a Chartered Accountant (CA) of Chartered Accountants Australia & New Zealand.

(Updated as at Sep 2024)